{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:39:28Z","timestamp":1794584368718,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20\u201350 years after exposure to asbestos and evolves along an unknown evolutionary trajectory. To elucidate this path, we conducted multi-regional exome sequencing of 90 tumour samples from 22 MPMs acquired at surgery. Here we show that exomic intratumour heterogeneity varies widely across the cohort. Phylogenetic tree topology ranges from linear to highly branched, reflecting a steep gradient of genomic instability. Using transfer learning, we detect repeated evolution, resolving 5 clusters that are prognostic, with temporally ordered clonal drivers.\n                    <jats:italic>BAP1<\/jats:italic>\n                    \/\u22123p21 and\n                    <jats:italic>FBXW7<\/jats:italic>\n                    \/-chr4 events are always\n                    <jats:italic>early<\/jats:italic>\n                    clonal. In contrast,\n                    <jats:italic>NF2<\/jats:italic>\n                    \/\u221222q events, leading to Hippo pathway inactivation are predominantly\n                    <jats:italic>late<\/jats:italic>\n                    clonal, positively selected, and when subclonal, exhibit parallel evolution indicating an evolutionary constraint. Very late somatic alteration of\n                    <jats:italic>NF2<\/jats:italic>\n                    \/22q occurred in one patient 12 years after surgery. Clonal architecture and evolutionary clusters dictate MPM inflammation and immune evasion. These results reveal potentially drugable evolutionary bottlenecking in MPM, and an impact of clonal architecture on shaping the immune landscape, with potential to dictate the clinical response to immune checkpoint inhibition.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-21798-w","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T09:05:27Z","timestamp":1616144727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment"],"prefix":"10.1038","volume":"12","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7413-6870","authenticated-orcid":false,"given":"Alan G.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Nakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Busacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-9151","authenticated-orcid":false,"given":"Annabel J.","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Sheaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wells-Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Poile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essa Y.","family":"Baitei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Bzura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-7687","authenticated-orcid":false,"given":"Joanna","family":"Dzialo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maymun","family":"Jama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Le Quesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-503X","authenticated-orcid":false,"given":"Jacqui A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-9300","authenticated-orcid":false,"given":"Tamihiro","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Kuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Brannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"De Philip Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-3631","authenticated-orcid":false,"given":"Hongji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-8908","authenticated-orcid":false,"given":"Frank","family":"Dudbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0115-2298","authenticated-orcid":false,"given":"Edward J.","family":"Hollox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-1312","authenticated-orcid":false,"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"21798_CR1","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner, J. C., Sleggs, C. A. & Marchand, P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 17, 260\u2013271 (1960).","journal-title":"Br. J. Ind. Med."},{"key":"21798_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/oemed-2017-104298","volume":"74","author":"CO Odgerel","year":"2017","unstructured":"Odgerel, C. O. et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup. Environ. Med. 74, 851\u2013858 (2017).","journal-title":"Occup. Environ. Med."},{"key":"21798_CR3","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","volume":"49","author":"DY Kircheva","year":"2016","unstructured":"Kircheva, D. Y. et al. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 49, 1642\u20131647 (2016).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"21798_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 397, 375\u2013386 (2021).","journal-title":"The Lancet."},{"key":"21798_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer 17, 475\u2013488 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"21798_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668\u2013672 (2011).","journal-title":"Nat. Genet."},{"key":"21798_CR7","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"21798_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","volume":"13","author":"J Jongsma","year":"2008","unstructured":"Jongsma, J. et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 13, 261\u2013271 (2008).","journal-title":"Cancer Cell"},{"key":"21798_CR9","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","volume":"76","author":"Y Kadariya","year":"2016","unstructured":"Kadariya, Y. et al. Bap1 Is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76, 2836\u20132844 (2016).","journal-title":"Cancer Res."},{"key":"21798_CR10","doi-asserted-by":"publisher","unstructured":"Badhai, J. et al. Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191257 (2020).","DOI":"10.1084\/jem.20191257"},{"key":"21798_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-019-1426-6","volume":"572","author":"J Wu","year":"2019","unstructured":"Wu, J. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 572, 402\u2013406 (2019).","journal-title":"Nature"},{"key":"21798_CR12","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109\u20132121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"21798_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"21798_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019).","journal-title":"Nature"},{"key":"21798_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271.e1211 (2017).","journal-title":"Cell"},{"key":"21798_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353\u2013357 (2015).","journal-title":"Nature"},{"key":"21798_CR17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ng.3573","volume":"48","author":"A McPherson","year":"2016","unstructured":"McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758\u2013767 (2016).","journal-title":"Nat. Genet."},{"key":"21798_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"21798_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"21798_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"21798_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.cell.2018.06.001","volume":"173","author":"I Martincorena","year":"2018","unstructured":"Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 173, 1823 (2018).","journal-title":"Cell"},{"key":"21798_CR22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022\u20131025 (2011).","journal-title":"Nat. Genet."},{"key":"21798_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/ng0693-175","volume":"4","author":"TH Rabbitts","year":"1993","unstructured":"Rabbitts, T. H., Forster, A., Larson, R. & Nathan, P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat. Genet. 4, 175\u2013180 (1993).","journal-title":"Nat. Genet."},{"key":"21798_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","volume":"44","author":"CE Barbieri","year":"2012","unstructured":"Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685\u2013689 (2012).","journal-title":"Nat. Genet."},{"key":"21798_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2016.08.003","volume":"30","author":"ZQ Guo","year":"2016","unstructured":"Guo, Z. Q. et al. Small-molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell 30, 474\u2013484 (2016).","journal-title":"Cancer Cell"},{"key":"21798_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41588-020-0584-7","volume":"52","author":"S Lopez","year":"2020","unstructured":"Lopez, S. et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat. Genet. 52, 283\u2013293 (2020).","journal-title":"Nat. Genet."},{"key":"21798_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41592-018-0108-x","volume":"15","author":"G Caravagna","year":"2018","unstructured":"Caravagna, G. et al. Detecting repeated cancer evolution from multi-region tumor sequencing data. Nat. Methods 15, 707\u2013714 (2018).","journal-title":"Nat. Methods"},{"key":"21798_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BST20160229","volume":"45","author":"S Venkatesan","year":"2017","unstructured":"Venkatesan, S., Birkbak, N. J. & Swanton, C. Constraints in cancer evolution. Biochem. Soc. Trans. 45, 1\u201313 (2017).","journal-title":"Biochem. Soc. Trans."},{"key":"21798_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","volume":"25","author":"P Courtiol","year":"2019","unstructured":"Courtiol, P. et al. Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat. Med. 25, 1519\u20131525 (2019).","journal-title":"Nat. Med."},{"key":"21798_CR30","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave, L. M. et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21, 1344\u20131349 (2015).","journal-title":"Nat. Med."},{"key":"21798_CR31","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","volume":"113","author":"Y Yoshikawa","year":"2016","unstructured":"Yoshikawa, Y. et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc. Natl Acad. Sci. USA 113, 13432\u201313437 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21798_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature09779","volume":"471","author":"IE Wertz","year":"2011","unstructured":"Wertz, I. E. et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110\u2013114 (2011).","journal-title":"Nature"},{"key":"21798_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka, H. et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104\u2013109 (2011).","journal-title":"Nature"},{"key":"21798_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","volume":"63","author":"J Stebbing","year":"2009","unstructured":"Stebbing, J. et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63, 94\u201397 (2009).","journal-title":"Lung Cancer"},{"key":"21798_CR35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell, D. A. et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study. J. Clin. Oncol. 37, 790\u2013798 (2019).","journal-title":"J. Clin. Oncol."},{"key":"21798_CR36","doi-asserted-by":"publisher","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro, I. M. et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci. Transl. Med. 6, 237ra268 (2014).","journal-title":"Sci. Transl. Med."},{"key":"21798_CR37","doi-asserted-by":"publisher","unstructured":"Tang, Y. et al. Selective inhibition of STRN3-containing PP2A phosphatase restores hippo tumor-suppressor activity in gastric cancer. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2020.05.019 (2020).","DOI":"10.1016\/j.ccell.2020.05.019"},{"key":"21798_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/d41586-019-02218-y","volume":"572","author":"D Fennell","year":"2019","unstructured":"Fennell, D. Cancer-cell death ironed out. Nature 572, 314\u2013315 (2019).","journal-title":"Nature"},{"key":"21798_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through yap-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122.e112 (2020).","journal-title":"Cancer Cell"},{"key":"21798_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12846-7","volume":"10","author":"D Su","year":"2019","unstructured":"Su, D. et al. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nat. Commun. 10, 5076 (2019).","journal-title":"Nat. Commun."},{"key":"21798_CR41","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","volume":"351","author":"KJ Mavrakis","year":"2016","unstructured":"Mavrakis, K. J. et al. Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208\u20131213 (2016).","journal-title":"Science"},{"key":"21798_CR42","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214\u20131218 (2016).","journal-title":"Science"},{"key":"21798_CR43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","volume":"15","author":"K Marjon","year":"2016","unstructured":"Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis. Cell Rep. 15, 574\u2013587 (2016).","journal-title":"Cell Rep."},{"key":"21798_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 18, 623\u2013630 (2017).","journal-title":"Lancet Oncol."},{"key":"21798_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel, A. et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 20, 239\u2013253 (2019).","journal-title":"Lancet Oncol."},{"key":"21798_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst, M. J. et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 7, 260\u2013270 (2019).","journal-title":"Lancet Respir. Med."},{"key":"21798_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2602-y","volume":"19","author":"DA Fennell","year":"2018","unstructured":"Fennell, D. A. et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials 19, 233 (2018).","journal-title":"Trials"},{"key":"21798_CR48","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"21798_CR49","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/nprot.2015.105","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang, H. & Wang, K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat. Protoc. 10, 1556\u20131566 (2015).","journal-title":"Nat. Protoc."},{"key":"21798_CR50","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/bioinformatics\/btv003","volume":"31","author":"S Malikic","year":"2015","unstructured":"Malikic, S., McPherson, A. W., Donmez, N. & Sahinalp, C. S. Clonality inference in multiple tumor samples using phylogeny. Bioinformatics 31, 1349\u20131356 (2015).","journal-title":"Bioinformatics"},{"key":"21798_CR51","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1093\/annonc\/mdx517","volume":"28","author":"HX Dang","year":"2017","unstructured":"Dang, H. X. et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Ann. Oncol. 28, 3076\u20133082 (2017).","journal-title":"Ann. Oncol."},{"key":"21798_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"21798_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal, J. et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol. Res. 8, 409\u2013420 (2020).","journal-title":"Cancer Immunol. Res."}],"updated-by":[{"DOI":"10.1038\/s41467-021-23867-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21798-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21798-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21798-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T21:05:43Z","timestamp":1675026343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21798-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21798"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21798-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-021-23867-6","URL":"https:\/\/doi.org\/10.1038\/s41467-021-23867-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1751"}}